SCLC Treatment - Overview

Treatment of SCLC (CHEST)
Abstract of the evidence-based lung cancer treatment guideline published by the American College of Chest Physicians (ACCP) in the supplement to the January 2003 issue of CHEST. Notes that SCLC is staged as limited-stage disease and extensive-stage disease. Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20% of patients achieving a cure. The median survival time for patients with limited-stage disease is approximately 18 months. Extensive-stage disease is treated primarily with chemotherapy, with a high initial response rate of 60 to 70% and a complete response rate of 20 to 30%, but with a median survival time of approximately 9 months. Patients achieving a complete remission should be offered prophylactic cranial irradiation. Additional recommendations and assessments are included. Aimed at physicians. [1/03]

Small-cell Lung Cancer (PubMed)
Abstract of a review article in the October 15-21 issue of Lancet that describes small-cell lung cancer, its nature, pathology, staging, treatment and follow-up. [10/05]

SCLC: State of the Art and Future Perspectives (PubMed)
Abstract of a review article in the July 2004 issue of Lung Cancer summarizing the state of the art and future perspectives in the detection, staging and treatment of SCLC. [7/04]

PDQ Small Cell Lung Cancer: Treatment Options Overview (National Cancer Institute)
Outline of treatment options for small cell lung cancer presented by stage. Aimed at patients. See also the healthcare professional version. [8/04]

Treatment of SCLC - Recent MEDLINE Abstracts